Goldman Sachs GS-0.82%decrease; red down pointing triangle announced a number of promotions in its global banking and markets division, signaling the rise of a next generation of leadership.

Goldman Sachs reiterated its Buy rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares with a steady price target of $78.00. The firm's analyst highlighted Ultragenyx's fourth-quarter total ...

we are pleased to have reached this agreement and delivered a significant outcome for our investors,” a spokesperson for Blackstone said in a statement to Commercial Observer. Spokespeople for Goldman ...

Plaid, a company that connects bank accounts to financial applications, is working with Goldman Sachs on a deal to allow early-stage investors and employees to sell existing shares, which will ...

Irvine-based Pendulum Property Partners acquired the 320,000-square-foot office building at 505 N. Brand Blvd. from a joint ...

Data Center Dynamics previously reported. Goldman Sachs, HMC and Newmark did not immediately return requests for comment.

Another potential implication is a stronger dollar, which would further hurt S&P 500 earnings because the companies get 28% ...

Goldman Sachs has rebounded significantly, with its stock up 116% since November 2023. The company's earnings exceeded expectations, driven by increased M&A and IPO activities. Some analysts ...

Goldman Sachs analysts have been examining the stock ... Don't Miss: Unlock the hidden potential of commercial real estate — This platform allows individuals to invest in commercial real estate ...